Skip to main content
Top
Published in: Journal of Gastroenterology 1/2015

Open Access 01-01-2015 | Original Article—Liver, Pancreas, and Biliary Tract

Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment

Authors: Yoshiyuki Sakai, Yoshinori Iwata, Hirayuki Enomoto, Masaki Saito, Kazunori Yoh, Akio Ishii, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Hironori Tanaka, Hiroko Iijima, Shuhei Nishiguchi

Published in: Journal of Gastroenterology | Issue 1/2015

Login to get access

Abstract

Background

The usefulness of branched-chain amino acid (BCAA) granules and BCAA-enriched nutrient mixtures for patients with liver cirrhosis is often reported. However, no randomized controlled studies have investigated the usefulness of these supplements in the nutritional intervention of cirrhotic patients receiving endoscopic treatment for esophageal varices.

Methods

Patients without BCAA before endoscopic treatment were divided into study 1, and those who received BCAA were divided into study 2. In study 1, 44 eligible patients were divided into a control group (n = 13), a general liquid nutrient (snack) group (n = 15), and a BCAA-enriched nutrient mixture (BCAA-EN) group (n = 16). In study 2, 48 eligible patients were divided into a BCAA group (n = 24) and a BCAA-EN group (n = 24). The nutritional status including non-protein respiratory quotient (NPRQ) levels, weight gain, and albumin were evaluated on days 0, 7, and 50.

Results

In study 1, the BCAA-EN group showed significant improvement in NPRQ levels on day 7 as compared with the snack group. In study 2, the BCAA-EN group showed significant improvement in NPRQ levels on day 7 and in weight levels on day 50 relative to the BCAA group, while the BCAA group showed improved serum albumin levels on day 7 compared to the BCAA-EN group.

Conclusions

The BCAA-enriched nutrient mixture maintained NPRQ and weight in cirrhotic patients. Our findings suggest that supplements including both BCAA and a nutritional energy supplement would be beneficial for cirrhotic patients undergoing endoscopic treatment for esophageal varices.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ashkenazi E, Kovalev Y, Zuckerman E. Evaluation and treatment of esophageal varices in the cirrhotic patient. Isr Med Assoc J. 2013;15:109–15.PubMed Ashkenazi E, Kovalev Y, Zuckerman E. Evaluation and treatment of esophageal varices in the cirrhotic patient. Isr Med Assoc J. 2013;15:109–15.PubMed
2.
go back to reference Lautz HU, Selberg O, Körber J, et al. Protein-calorie malnutrition in liver cirrhosis. Clin Invest. 1992;70:478–86.CrossRef Lautz HU, Selberg O, Körber J, et al. Protein-calorie malnutrition in liver cirrhosis. Clin Invest. 1992;70:478–86.CrossRef
3.
go back to reference Caregaro L, Alberino F, Amodio P, et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr. 1996;63:602–9.PubMed Caregaro L, Alberino F, Amodio P, et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr. 1996;63:602–9.PubMed
4.
go back to reference Tajika M, Kato M, Mohri H, et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition. 2002;18:229–34.PubMedCrossRef Tajika M, Kato M, Mohri H, et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition. 2002;18:229–34.PubMedCrossRef
5.
go back to reference Huisman EJ, Trip EJ, Siersema PD, et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol. 2011;23:982–9.PubMedCrossRef Huisman EJ, Trip EJ, Siersema PD, et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol. 2011;23:982–9.PubMedCrossRef
6.
go back to reference Singh P, Pooran N, Indaram A, et al. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis. Am J Gastroenterol. 2002;97:623–9.PubMedCrossRef Singh P, Pooran N, Indaram A, et al. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis. Am J Gastroenterol. 2002;97:623–9.PubMedCrossRef
7.
go back to reference Svoboda P, Kantorová I, Ochmann J, et al. A prospective randomized controlled trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. Surg Endosc. 1999;13:580–4.PubMedCrossRef Svoboda P, Kantorová I, Ochmann J, et al. A prospective randomized controlled trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. Surg Endosc. 1999;13:580–4.PubMedCrossRef
8.
go back to reference Iso Y, Kawanaka H, Tomikawa M, et al. Repeated injection sclerotherapy is preferable to combined therapy with variceal ligation to avoid recurrence of esophageal varices. Hepatogastroenterology. 1997;44:467–71.PubMed Iso Y, Kawanaka H, Tomikawa M, et al. Repeated injection sclerotherapy is preferable to combined therapy with variceal ligation to avoid recurrence of esophageal varices. Hepatogastroenterology. 1997;44:467–71.PubMed
9.
go back to reference Katsumi N, Kawamura N, Yamaguchi Y, et al. Effect of oral branched chain amino acid-rich nutrient administered during endoscopic infection sclerotherapy of cirrhotic patients. Hepatol Res. 2005;32:158–62.PubMedCrossRef Katsumi N, Kawamura N, Yamaguchi Y, et al. Effect of oral branched chain amino acid-rich nutrient administered during endoscopic infection sclerotherapy of cirrhotic patients. Hepatol Res. 2005;32:158–62.PubMedCrossRef
10.
go back to reference Shibata N, Matsui H, Onji M, et al. Usefulness of BCAA-enriched nutrient mixture for nutritional treatment undergoing endoscopic treatment for esophageal varices. J Jpn Soc Gastroenterol. 2005;32:158–62. Shibata N, Matsui H, Onji M, et al. Usefulness of BCAA-enriched nutrient mixture for nutritional treatment undergoing endoscopic treatment for esophageal varices. J Jpn Soc Gastroenterol. 2005;32:158–62.
11.
go back to reference Nagata N, Numata M, Hirose S, et al. Nutritional assessment after treatment of esophageal varices in patients with Cirrhosis. Jpn J Portal Hypertens. 2008;14:201–5. Nagata N, Numata M, Hirose S, et al. Nutritional assessment after treatment of esophageal varices in patients with Cirrhosis. Jpn J Portal Hypertens. 2008;14:201–5.
12.
go back to reference Muto Y, Sato S, Watanabe A, et al. Effect of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3:705–13.PubMedCrossRef Muto Y, Sato S, Watanabe A, et al. Effect of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3:705–13.PubMedCrossRef
13.
go back to reference Yoshida T, Muto Y, Moriwaki H, et al. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Jpn. 1989;24:692–8.PubMed Yoshida T, Muto Y, Moriwaki H, et al. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Jpn. 1989;24:692–8.PubMed
14.
go back to reference Habu D, Nishiguchi S, Nakatani S, et al. Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. Hepatol Res. 2003;25:312–8.PubMedCrossRef Habu D, Nishiguchi S, Nakatani S, et al. Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. Hepatol Res. 2003;25:312–8.PubMedCrossRef
15.
go back to reference Muto Y, Yoshida T, Kato M, et al. Effect of oral supplementation with BCAA-G on the prognosis of liver cirrhosis. JJPEN. 1995;17:1135–43. Muto Y, Yoshida T, Kato M, et al. Effect of oral supplementation with BCAA-G on the prognosis of liver cirrhosis. JJPEN. 1995;17:1135–43.
16.
go back to reference Muto Y, Sato S, Watanabe A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 2006;35:204–14.PubMed Muto Y, Sato S, Watanabe A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 2006;35:204–14.PubMed
17.
go back to reference Kobayashi M, Ikeda K, Arase Y, et al. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol. 2008;43:63–70.PubMedCrossRef Kobayashi M, Ikeda K, Arase Y, et al. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol. 2008;43:63–70.PubMedCrossRef
18.
go back to reference Kawaguchi T, Yamagishi S, Sata M. Branched-chain amino acid and pigment epithelium-derived factor: novel therapeutic agents for hepatitis c virus-associated insulin resistance. Curr Med Chem. 2009;16:4843–57.PubMedCrossRef Kawaguchi T, Yamagishi S, Sata M. Branched-chain amino acid and pigment epithelium-derived factor: novel therapeutic agents for hepatitis c virus-associated insulin resistance. Curr Med Chem. 2009;16:4843–57.PubMedCrossRef
19.
go back to reference Tsuchiya M, Sakaida I, Okamoto M, et al. The effect of a late evening snack in patients with liver cirrhosis. Hepatol Res. 2005;31:95–103.PubMedCrossRef Tsuchiya M, Sakaida I, Okamoto M, et al. The effect of a late evening snack in patients with liver cirrhosis. Hepatol Res. 2005;31:95–103.PubMedCrossRef
20.
go back to reference Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves nutritional stage of cirrhosis. Nutrition. 2007;23:113–20.PubMedCrossRef Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves nutritional stage of cirrhosis. Nutrition. 2007;23:113–20.PubMedCrossRef
21.
go back to reference Yamanaka-Okumura H, Nakamura T, Takeuchi H, et al. Effect of late evening snack with rice ball on energy metabolism in liver cirrhosis. Eur J Clin Nutr. 2006;60:1067–72.PubMedCrossRef Yamanaka-Okumura H, Nakamura T, Takeuchi H, et al. Effect of late evening snack with rice ball on energy metabolism in liver cirrhosis. Eur J Clin Nutr. 2006;60:1067–72.PubMedCrossRef
22.
go back to reference Aoyama K, Tsuchiya M, Mori K, et al. Effect of a late evening snack on outpatients with liver cirrhosis. Hepatol Res. 2007;37:608–14.PubMedCrossRef Aoyama K, Tsuchiya M, Mori K, et al. Effect of a late evening snack on outpatients with liver cirrhosis. Hepatol Res. 2007;37:608–14.PubMedCrossRef
23.
go back to reference Nakaya Y, Harada N, Kakui S, et al. Severe catabolic state after prolonged fasting in cirrhotic patients: effect of oral branched-chain amino-acid-enriched nutrient mixture. J Gastroenterol. 2002;37:531–6.PubMedCrossRef Nakaya Y, Harada N, Kakui S, et al. Severe catabolic state after prolonged fasting in cirrhotic patients: effect of oral branched-chain amino-acid-enriched nutrient mixture. J Gastroenterol. 2002;37:531–6.PubMedCrossRef
24.
go back to reference Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17:445–50.PubMedCrossRef Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17:445–50.PubMedCrossRef
25.
go back to reference Müller MJ. Malnutrition in cirrhosis. J Hepatol. 1995;23(Suppl 1):31–5.PubMed Müller MJ. Malnutrition in cirrhosis. J Hepatol. 1995;23(Suppl 1):31–5.PubMed
26.
go back to reference Miwa Y, Shiraki M, Kato M, et al. Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis. Hepatol Res. 2000;18:184–9.PubMedCrossRef Miwa Y, Shiraki M, Kato M, et al. Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis. Hepatol Res. 2000;18:184–9.PubMedCrossRef
27.
go back to reference Hidaka H, Nakazawa T, Kutsukake S, et al. The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis. J Gastroenterol. 2013;48:269–76.PubMedCrossRef Hidaka H, Nakazawa T, Kutsukake S, et al. The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis. J Gastroenterol. 2013;48:269–76.PubMedCrossRef
28.
go back to reference Sato S, Watanabe A, Muto Y, et al. Clinical comparison of branched-chain amino acid (l-leucine, l-isoleucine, l-valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN study). Hepatol Res. 2005;31:232–40.PubMedCrossRef Sato S, Watanabe A, Muto Y, et al. Clinical comparison of branched-chain amino acid (l-leucine, l-isoleucine, l-valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN study). Hepatol Res. 2005;31:232–40.PubMedCrossRef
29.
go back to reference Urata Y, Okita K, Korenaga K, et al. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. Hepatol Res. 2007;37:510–6.PubMedCrossRef Urata Y, Okita K, Korenaga K, et al. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. Hepatol Res. 2007;37:510–6.PubMedCrossRef
30.
go back to reference Kato M, Miwa Y, Tajika M, et al. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Intern Med. 1998;37:429–34.PubMedCrossRef Kato M, Miwa Y, Tajika M, et al. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Intern Med. 1998;37:429–34.PubMedCrossRef
31.
go back to reference Merli M, Riggio R, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology. 1996;23:1041–6.PubMedCrossRef Merli M, Riggio R, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology. 1996;23:1041–6.PubMedCrossRef
32.
go back to reference Ijichi C, Matsumura T, Tsuji T, et al. Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. Biochem Biophys Res Commun. 2003;303:59–64.PubMedCrossRef Ijichi C, Matsumura T, Tsuji T, et al. Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. Biochem Biophys Res Commun. 2003;303:59–64.PubMedCrossRef
33.
go back to reference Owen OE, Reichle FA, Mozzoli MA, et al. Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. J Clin Invest. 1981;68:240–52.PubMedCentralPubMedCrossRef Owen OE, Reichle FA, Mozzoli MA, et al. Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. J Clin Invest. 1981;68:240–52.PubMedCentralPubMedCrossRef
Metadata
Title
Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment
Authors
Yoshiyuki Sakai
Yoshinori Iwata
Hirayuki Enomoto
Masaki Saito
Kazunori Yoh
Akio Ishii
Tomoyuki Takashima
Nobuhiro Aizawa
Naoto Ikeda
Hironori Tanaka
Hiroko Iijima
Shuhei Nishiguchi
Publication date
01-01-2015
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2015
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-014-0950-2

Other articles of this Issue 1/2015

Journal of Gastroenterology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.